Ciprofloxacin pharmacokinetics and oral absorption of generic ciprofloxacin tablets in dogs

American Journal of Veterinary Research

Volumn 73, Issue 7, 2012, Pages 1085-1091

  Papich, Mark G ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GENERIC DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COMPARTMENT MODEL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; DRUG TOLERABILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SMALL INTESTINE; STOMACH TUBE; STUDY DESIGN; TABLET;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CIPROFLOXACIN; CROSS-OVER STUDIES; DOGS; DRUGS, GENERIC; HALF-LIFE; RANDOM ALLOCATION; TABLETS;

ANIMALIA; CANIS FAMILIARIS;

EID: 84863486522     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.73.7.1085     Document Type: Article

References (31)

1. Abadía AR, Aramayona JJ, Muñoz MJ, et al. Ciprofloxacin pharmacokinetics in dogs following oral administration. Zentralbl Veterinarmed A 1995;42:505-511.
2. Abadía AR, Aramayona JJ, Muñoz MJ, et al. Disposition of ciprofloxacin following intravenous administration in dogs. J Vet Pharmacol Ther 1994;17:384-388.
3. Walker RD, Stein GE, Hauptman JG, et al. Serum and tissue cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs. Am J Vet Res 1990;51:896-900.
4. Nakamura S, Kurobe N, Ohue T, et al. Pharmacokinetics of a novel quinolone, AT-4140, in animals. Antimicrob Agents Chemother 1990;34:89-93.
5. Papich MG, Riviere JE. Chapter 38. Fluoroquinolone antimicrobial drugs. In: Riviere JE, Papich MG, eds. Veterinary pharmacology and therapeutics. 9th ed. Ames, Iowa: Wiley-Blackwell Publishing, 2009;1524.
6. Plaisance KI, Drusano GL, Forrest A, et al. Effect of dose size on bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1987;31:956-958.
7. Khan MK, Khan MF, Khan H, et al. Bioavailability of ciprofloxacin tablets in humans and its correlation with the dissolution rates. Pak J Pharm Sci 2009;22:329-334.
8. Albarellos GA, Kreil VE, Landoni MF. Pharmacokinetics of ciprofloxacin after single intravenous and repeat oral administration to cats. J Vet Pharmacol Ther 2004;27:155-162.
9. Yamarik TA, Wilson WD, Wiebe VJ, et al. Pharmacokinetics and toxicity of ciprofloxacin in adult horses. J Vet Pharmacol Ther 2010;33:587-594.
10. Plumb DC. Plumb's veterinary drug handbook. 6th ed. Ames, Iowa: Blackwell Publishing, 2008;1120.
11. Papich MG. Saunders handbook of veterinary drugs. 3rd ed. St Louis: Elsevier-Saunders, 2011;858.
12. Bidgood T, Papich MG. Plasma and interstitial fluid pharmacokinetics of enrofloxacin, its metabolite ciprofloxacin, and marbofloxacin after oral administration and a constant rate intravenous infusion in dogs. J Vet Pharmacol Ther 2005;28:329-341.
13. Davis JL, Foster DM, Papich MG. Pharmacokinetics and tissue distribution of enrofloxacin and its active metabolite ciprofloxacin in calves. J Vet Pharmacol Ther 2007;30:564-571.
14. United States Pharmacopeia (USP-NF). USP34-NF29. General chapter on validation of compendial procedures <1225>. Rockville, Md: United States Pharmacopeial Convention, 2011.
15. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-175.
16. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc, 1982.
17. Shaheen BW, Boothe DM, Oyarzabal OA, et al. Evaluation of the contribution of gyrA mutation and efflux pumps to fluoroquinolone and multidrug resistance in pathogenic Escherichia coli isolates from dogs and cats. Am J Vet Res 2011;72:25-32.
18. Jensen US, Muller A, Brandt CT, et al. Effect of generics on price and consumption of ciprofloxacin in primary healthcare: the relationship to increasing resistance. J Antimicrob Chemother 2010;65:1286-1291.
19. Martinez MN, Papich MG. Factors influencing the gastric residence of dosage forms in dogs. J Pharm Sci 2009;98:844-860.
20. Overholser BR, Kays MB, Forrest A, et al. Sex-related differences in the pharmacokinetics of oral ciprofloxacin. J Clin Pharmacol 2004;44:1012-1022.
21. Kasim NA, Whitehouse M, Ramachandran C, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004;1:85-96.
22. Stahlmann R, Kühner S, Shakibaei M, et al. Chondrotoxicity of ciprofloxacin in immature Beagle dogs: immunohistochemistry, electron microscopy and drug plasma concentrations. Arch Toxicol 2000;73:564-572.
23. Shugarts S, Benet LZ. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 2009;26:2039-2054.
24. Ashby J, Piddock LJV, Wise R. An investigation of the hydrophobicity of the quinolones. J Antimicrob Chemother 1985;16:805-808.
25. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005;22:11-23.
26. Žakelj S, Šturm K, Kristl A. Ciprofloxacin permeability and its active secretion through rat small intestine in vitro. Int J Pharm 2006;313:175-180.
27. AliAbadi FS, Lees P. Antibiotic treatment for animals: effect on bacterial population and dosage regimen optimization. Int J Antimicrob Agents 2000;14:307-313.
28. Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002;19:261-268.
29. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004;2:289-300.
30. McKellar QA, Sanchez Bruni SF, Jones DG. Pharmacokinetic/ pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine. J Vet Pharmacol Ther 2004;27:503-514.
31. Zelenitsky SA, Ariano RE. Support for higher ciprofloxacin AUC24/MIC targets in treating Enterobacteriaceae bloodstream infection. J Antimicrob Chemother 2010;65:1725-1732.